VA-HILTON-EFFECT
22.10.2020 16:02:05 CEST | Business Wire | Press release
The Hilton Effect Foundation announced today its 2020 Hilton Effect grantees, which include community-based organizations playing a direct role in COVID-19 pandemic recovery efforts. Through these grants and donations already made by the Foundation, which serves as Hilton ’s primary philanthropic arm, the Foundation has now awarded more than $1 million dollars in COVID-19 community response efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005724/en/
“A core part of the Hilton Effect Foundation’s work is to support our communities around the world through both good times and bad,” said Kate Mikesell, president, Hilton Effect Foundation. “From the very start of the pandemic, we have been listening to community leaders about the direct and indirect challenges they are facing as a result of COVID-19. Based on their feedback, we have focused our grants on driving inclusive recovery and strengthening community resiliency.”
The Hilton Effect Foundation’s grants aim to address some of the most urgent humanitarian needs arising from the pandemic: food security, sanitation/hygiene, economic security and clean air and water. Consistent with Hilton’s commitment to respecting human rights, driving racial equality and promoting inclusive growth for all, the Foundation prioritized organizations addressing these needs, while also directly supporting minority populations and other vulnerable communities that have been disproportionately impacted by the pandemic.
Terence Lester, executive director of grant recipient Love Beyond Walls, which works to raise awareness of societal needs and support disadvantaged individuals, including those experiencing homelessness, said, “We’re all interconnected and can help one another during challenging times. This is why it’s critical for organizations like Love Beyond Walls to join forces with the Hilton Effect Foundation in order to support local communities that have been severely impacted by the global pandemic. Together, we can make a difference and create a more equitable and inclusive world.”
The 23 grants have been awarded in the following categories:
Food Security: The United Nations World Food Programme predicts that the number of people facing acute food insecurity could nearly double this year to 265 million due to the economic fallout of COVID-19. The Foundation has awarded grants to the following organizations addressing this need:
- Food Forward (United States)
- Harvest Against Hunger (United States)
- Musubie (Japan)
- Scholars of Sustenance (Thailand)
- Wildlife and Environment Society of South Africa (South Africa)
Sanitation and Hygiene: Handwashing is the most effective way to prevent the spread of COVID-19, yet many communities around the world lack access to clean water and basic hygiene products such as soap. The Foundation has funded the following grantees that help bring water, sanitation and hygiene (WASH) practices to communities around the world and promote effective hygiene:
- Eco-Soap Bank (Africa)
- Emmanuel Foundation (Indonesia)
- Habitat for Humanity Fiji (Fiji)
- Love Beyond Walls (United States)
- Water.org (Brazil)
Economic Security: COVID-19 has had a disproportionate and devastating impact on the employment status and economic security of vulnerable populations around the world. The Foundation has funded the following organizations that are creating and providing inclusive opportunities for these populations, including training and employment programs:
- ACE Charity (Nigeria)
- BCAGlobal (United States)
- Springboard (United Kingdom)
- International Rescue Committee (Jordan)
- KARI Foundation (Australia)
- Lligam (Spain)
- My Block, My Hood, My City (United States)
Clean Air and Water: The communities that are hardest hit by racial and social injustice have also been disproportionately impacted by the climate crisis, environmental pollution and now COVID-19. The Foundation awarded grants to the following organizations to advance environmental protection, with a focus on furthering environmental justice and addressing those concerns in underserved communities:
- Ecamir (Russia)
- National Environmental Education Foundation (United States)
- Planet Water Foundation (India)
- Student Conservation Association (United States)
- The Nature Conservancy (Peru and China)
To learn more about the Hilton Effect Foundation and this year’s grantees please visit: https://hiltoneffect.org/grantees/
About Hilton Effect Foundation
The Hilton Effect Foundation is Hilton’s primary international philanthropic arm. The Foundation is a nonprofit established in the U.S. and is a registered 501(c)3 charitable organization. The Foundation awards grants, in alignment with Hilton’s Travel with Purpose 2030 Goals , that have a positive impact on travel destinations around the world. Foundation grants are awarded throughout the year in accordance with tax and legal requirements. Visit HiltonEffect.org for more information.
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,200 properties with more than 983,000 rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the 108 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005724/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
